Meibomian gland dysfunction

Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Retrieved on: 
Tuesday, April 2, 2024
IOP, Gland, Signs, Ciclosporin, Glaucoma, LHT, Wills Eye Hospital, ASCRS, BCEC, Patient, Telecanthus, Meibomian gland dysfunction, Doctor of Philosophy, MD, GEMINI, DED, OMNI, Signs and symptoms, Safety, Poster, Pharmaceutical industry

MENLO PARK, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, announced today that data from studies of two of its proprietary glaucoma and dry eye technologies, the OMNI Surgical System (“OMNI”) and the TearCare System (“TearCare”), will be presented in two oral presentations and two posters at this year’s ASCRS Annual meeting April 5th to 8th in Boston, MA.

Key Points: 
  • OMNI technology facilitates surgeons’ ability to perform a comprehensive, implant-free, minimally invasive glaucoma surgical procedure in adults with primary open-angle glaucoma (“POAG”).
  • Lead author: Julio Echegoyen, MD, PhD
    Localized Heat Therapy (LHT) Compared to Cyclosporine Ophthalmic Emulsion (CsA): A Subanalysis on Age, Gender, and Disease Burden (SAHARA subanalysis) – poster presentation.
  • The event will be on Saturday, April 6, 2024, from 3:45 PM to 4:30 PM ET.
  • Learn more about this and other Sight Sciences activities at ASCRS at www.sightsciences.com/ascrs

EyeCare Partners Announces New Refractive Cataract Anterior Segment Fellowship and Launch of ECP Foundation

Retrieved on: 
Thursday, April 4, 2024
Optical, Surgery, Health, Other Education, Philanthropy, Education, Foundation, Training, Disease burden, Partner, ECP, RCAS, Density, Intraocular lens, Growth, Convention, Refractive surgery, Physician, ASCRS, Telecanthus, Knowledge, Research, Meibomian gland dysfunction, Fellow, Trifocal lenses, Science, Patient satisfaction, Cataract, Mentorship, Quality of life, Surgeon, Society, Ophthalmology, Nursing

EyeCare Partners (ECP), the nation’s leading provider of clinically integrated eye care, continues to advance leadership and research at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting.

Key Points: 
  • EyeCare Partners (ECP), the nation’s leading provider of clinically integrated eye care, continues to advance leadership and research at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting.
  • The company is launching two new initiatives to elevate eye care – the Refractive Cataract Anterior Segment (RCAS) Fellowship and the ECP Foundation.
  • This one-year program provides residency graduates comprehensive training in the latest advancements in refractive cataract and anterior segment surgeries.
  • “We implement this mission through three programs: ECP GIVES, ECP EDUCATES and ECP CARES,” said Amy Jones, ECP Foundation President.

Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease

Retrieved on: 
Monday, December 18, 2023
Patient, Entrepreneurship, Principal, Ophthalmology, Health, MD, Clinical trial, Inflammation, Randomized controlled trial, Gland, Keratoconjunctivitis, Telecanthus, Medicare, OSDI, Meibomian gland dysfunction, Test management, RCT

“We are extremely pleased to have the successful six-month results of the SAHARA RCT now published in a peer-reviewed journal.

Key Points: 
  • “We are extremely pleased to have the successful six-month results of the SAHARA RCT now published in a peer-reviewed journal.
  • The data from this trial support our belief in the clinical efficacy of interventional eyelid procedures enabled by TearCare technology versus the most commonly prescribed dry eye therapeutic for meibomian gland dysfunction,” said Paul Badawi, Co-Founder and Chief Executive Officer of Sight Sciences.
  • SAHARA included 345 subjects at 19 sites in 11 states randomized 1:1 to either TearCare or Restasis.
  • TearCare and Restasis also delivered comparable statistically significant clinical improvements in OSDI scores, Symptoms Assessment in Dry Eye (“SANDE”) scores, and Eye Dryness Scores (“EDS”), patient reported outcomes to subjectively assess dry eye severity.

Azura Ophthalmics Announces Positive Results from Phase 2 Clinical Trial of AZR-MD-001 in Patients with Contact Lens Discomfort

Retrieved on: 
Monday, December 18, 2023
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Contact lens, CLD, Meibomian gland dysfunction, Safety, Gland, Lens, Eyelid, Irritation, AZR, Dry, Patient, FDA, Ophthalmic, Fluorescein, Contact, MGD, MGS, Pain, Quality of life, Telescopic sight, Azura

This is the second positive Phase 2 study of AZR-MD-001 to demonstrate statistically significant improvements across multiple sign and symptom endpoints in patients with MGD.

Key Points: 
  • This is the second positive Phase 2 study of AZR-MD-001 to demonstrate statistically significant improvements across multiple sign and symptom endpoints in patients with MGD.
  • “MGD is the root cause of many downstream ocular surface conditions that impact quality of life and vision for patients, including Contact Lens Discomfort.
  • This leads to several downstream ocular surface symptoms including dryness, pain, irritation, reduced quality of vision, and Contact Lens Discomfort.
  • “MGD is one of the causes of Contact Lens Discomfort, and many patients give up on wearing contact lenses altogether due to the irritation they experience.

ThermaMEDx Introduces Clinically Proven EverTears Dry Eye Therapy Exclusively at Walgreens

Retrieved on: 
Monday, September 25, 2023
Optics, Honey, Salt, Walgreens, Meibomian gland dysfunction, Interview, Telecanthus, MGD, Water, Telescopic sight

ATLANTA, Sept. 25, 2023 /PRNewswire/ -- After two years of clinical success in Doctors' offices across the US, ThermaMEDx proudly announces the launch of its clinically proven treatment for dry eyes, EverTears, exclusively at Walgreens in a 10-count package. This new offering underscores the brand's commitment to making top-tier eye care solutions both accessible and convenient for the millions of Americans suffering from dry eyes.

Key Points: 
  • ATLANTA, Sept. 25, 2023 /PRNewswire/ -- After two years of clinical success in Doctors' offices across the US, ThermaMEDx proudly announces the launch of its clinically proven treatment for dry eyes, EverTears, exclusively at Walgreens in a 10-count package.
  • Historically, eye drops or "artificial tears" have been the primary choice for those seeking dry eye relief.
  • EverTears can be found on the middle shelf in the eye care section of select Walgreens stores.
  • EverTears offers a modern, clinically proven approach to dry eye relief.

ThermaMEDx Co-founder Ben Nobles Joins Select Group at the 2023 PERC Elevate Dry Eye Workshop

Retrieved on: 
Wednesday, September 20, 2023
DED, Curriculum, DRS, Research, Trial of the century, Meibomian gland dysfunction, Alcon, PERC, Heat, Conference, MGD, Pharmaceutical industry, Medical device, Nursing

ATLANTA, Sept. 20, 2023 /PRNewswire/ -- ThermaMEDx LLC proudly announces the participation of its co-founder, Ben Nobles, at the PERC 2023 Elevate National Meeting.

Key Points: 
  • ATLANTA, Sept. 20, 2023 /PRNewswire/ -- ThermaMEDx LLC proudly announces the participation of its co-founder, Ben Nobles, at the PERC 2023 Elevate National Meeting.
  • Guided by the esteemed Dr. Milton Hom, the Dry Eye Workshop offered attendees insights into the latest research surrounding DED and MGD causes and solutions.
  • Mr. Nobles was among the select few industry experts invited to this exclusive three-day conference by Drs.
  • "The Elevate Dry Eye Workshop was invaluable for PERC members," said Mr. Nobles.

Bausch + Lomb Launches MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) in the United States

Retrieved on: 
Tuesday, September 12, 2023
Science, Biotechnology, Research, Pharmaceutical, Optical, Health, FDA, Clinical Trials, Contact, DED, Bausch & Lomb, Telecanthus, Patient, Meibomian gland dysfunction, International Consumer Research & Testing, NYSE, Inflammation, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, MGD, Pharmaceutical industry, Telescopic sight

MIEBO is the first and only prescription eye drop approved for DED that directly targets tear evaporation.

Key Points: 
  • MIEBO is the first and only prescription eye drop approved for DED that directly targets tear evaporation.
  • “More and more Americans are suffering from dry eye disease, due in large part to today’s multi-screen lifestyles,” said Andrew Stewart, president, Global Pharmaceuticals and International Consumer, Bausch + Lomb.
  • The most common adverse reactions experienced with MIEBO was blurred vision (1% to 3% of patients reported blurred vision and eye redness).
  • MIEBO™ (perfluorohexyloctane ophthalmic solution) is used to treat the signs and symptoms of dry eye disease.

Exploring the Demodex Blepharitis Market: Clinical Viewpoints, Pipeline Evaluation, and Market Access Services | Disease Landscape Insights

Retrieved on: 
Monday, September 11, 2023
Infection, Pharma, Chalazion, Eyelash, Ocular rosacea, Signs and symptoms, Research, Inflammation, IgG4-related ophthalmic disease, Causes, Eyelid, DLI, Biological soil crust, Immune system, Growth, MITES, Ageing, Patient, Itch, Diagnosis, Stye, Meibomian gland dysfunction, Gland, FDA, R, Red, NIH, Skin, NME, Disease, Cosmetics, Agriculture, Medical device, Pharmaceutical industry, Demodex

Demodex Blepharitis is an inflammatory eye disorder caused by the uncontrollable growth of tiny mites known as Demodex on our eyelids.

Key Points: 
  • Demodex Blepharitis is an inflammatory eye disorder caused by the uncontrollable growth of tiny mites known as Demodex on our eyelids.
  • We at Disease Landscape Insights (DLI) aim to assist our clientele in understanding the characteristics of this disease and help them develop cutting edge treatment solutions.
  • Unlocking Insights into Demodex Blepharitis – From Research to Treatment Solutions, Dive Deeper into Managing this Eye Condition.
  • According to a data released by NIH, around 41% to 70% of the world's population are affected or highly prone to Demodex Blepharitis .

Prevent Blindness Declares July as Dry Eye Awareness Month to Educate Public on Eye Disease that Affects more than 16 Million Americans

Retrieved on: 
Thursday, July 20, 2023
Cornea, Medicine, Risk factor, Diuretic, Diabetes, Allergy, NEI, Visual impairment, OD, Anxiety, Social media, Eye, American Academy, American Academy of Ophthalmology, Lupus, Sjögren syndrome, Computer, Graves' ophthalmopathy, Telecanthus, Patient, Risk, National Eye Institute, Health, Meibomian gland dysfunction, MGD, Rheumatoid arthritis, Personal protective equipment, Cosmetics, Ophthalmology

CHICAGO, July 20, 2023 /PRNewswire-PRWeb/ -- Nearly 16 million Americans have dry eye, according to the National Eye Institute (NEI). Dry eye occurs when there is not enough tear film produced, the tear film is not draining properly from the eye, or the tear film is not the quality needed to maintain the health of the eye. If left untreated, dry eye can cause damage to the cornea.

Key Points: 
  • In an effort to educate the public on dry eye, Prevent Blindness , the nation's leading nonprofit eye health organization, has declared July as "Dry Eye Awareness Month."
  • Patients must inform their eyecare professional of all medications they are taking in order to treat dry eye and other eye conditions effectively.
  • "Dry eye is a serious condition that may have long-term effects on eye health, if left untreated," said Jeff Todd, president and CEO of Prevent Blindness.
  • For more information on dry eye, please visit the Prevent Blindness resource page at PreventBlindness.org/understanding-dry-eye .

Senju Pharmaceutical and Novaliq Enter Into License Agreement For NOV03 (Perfluorohexyloctane Ophthalmic Solution) For the Treatment of Dry Eye Disease in Japan

Retrieved on: 
Tuesday, June 13, 2023
Pharmaceutical, Health, Optical, Therapy, Meibomian gland dysfunction, Medication, History, Telecanthus, Patient, Ophthalmology, Safety, Pharmaceutical industry

“We are thrilled to collaborate with Novaliq as a pioneer for cutting edge water-free eye drop technology.

Key Points: 
  • “We are thrilled to collaborate with Novaliq as a pioneer for cutting edge water-free eye drop technology.
  • NOV03 is a first-in-class, preservative-free treatment for signs and symptoms of dry eye disease.
  • In Japan, potentially more than 5 million patients are diagnosed with dry eye disease [1] and current treatment options addressing evaporative dry eye disease or dry eye associated with clinical signs of Meibomian gland dysfunction are limited.
  • “We are proud to partner with Senju Pharmaceutical, a leading ophthalmic company in Japan, to bring NOV03 to patients in Japan”, said Dr. Christian Roesky, CEO, Novaliq.